Fat mass lowers the response to tumor necrosis factor-a blockers in patients with ankylosing spondylitis

Sebastián E.Ibáñez Vodnizza, Michael T. Nurmohamed, Ingrid M. Visman, J. Christiaan Van Denderen, Willem F. Lems, Francisca Jaime, Irene E. Van Der Horst-Bruinsma

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective. Our main objective was to assess the relationship between body composition (BC) and response to tumor necrosis factor-a (TNF-a) blocker treatment in patients with ankylosing spondylitis (AS). Our secondary objective was to evaluate the change of BC after treatment, accounting for sex and age. Methods. All included patients fulfilled the modified New York criteria for AS and were naive to TNF-a blocker. They were followed for at least 6 months after the start of etanercept or adalimumab. The Ankylosing Spondylitis Disease Activity Score containing C-reactive protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were reported. BC was assessed by whole body dual-energy X-ray absorptiometry. Body fat percentage (BF%), fat mass index (FMI), and fat free mass index (FFMI) were reported as absolute values and as percentiles. Results. Forty-one patients were included (61% men). The median followup was 14.3 months (interquartile range 8.4-19.4). After multivariate regression analysis, more fat at baseline (BF%, FMI, or FMI percentile) was significantly related with a lower chance of achieving a clinically important improvement of the ASDAS-CRP or BASDAI after treatment. The body composition did not change significantly after treatment, but there was a trend toward muscle recovery in men (FFMI change from 34.0th to 37.4th percentile). Conclusion. Higher body fat content at baseline was independently associated with a worse response to treatment with TNF-a blockers, measured by ASDAS-CRP and BASDAI change, and might contribute to the lower response rates in female patients. Also, there is a trend toward muscle mass recovery in male patients after treatment.

Original languageEnglish
Pages (from-to)1355-1361
Number of pages7
JournalJournal of Rheumatology
Volume44
Issue number9
DOIs
Publication statusPublished - 1 Sep 2017

Cite this

@article{b48cd4a82e95454c8d52566b7552deb6,
title = "Fat mass lowers the response to tumor necrosis factor-a blockers in patients with ankylosing spondylitis",
abstract = "Objective. Our main objective was to assess the relationship between body composition (BC) and response to tumor necrosis factor-a (TNF-a) blocker treatment in patients with ankylosing spondylitis (AS). Our secondary objective was to evaluate the change of BC after treatment, accounting for sex and age. Methods. All included patients fulfilled the modified New York criteria for AS and were naive to TNF-a blocker. They were followed for at least 6 months after the start of etanercept or adalimumab. The Ankylosing Spondylitis Disease Activity Score containing C-reactive protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were reported. BC was assessed by whole body dual-energy X-ray absorptiometry. Body fat percentage (BF{\%}), fat mass index (FMI), and fat free mass index (FFMI) were reported as absolute values and as percentiles. Results. Forty-one patients were included (61{\%} men). The median followup was 14.3 months (interquartile range 8.4-19.4). After multivariate regression analysis, more fat at baseline (BF{\%}, FMI, or FMI percentile) was significantly related with a lower chance of achieving a clinically important improvement of the ASDAS-CRP or BASDAI after treatment. The body composition did not change significantly after treatment, but there was a trend toward muscle recovery in men (FFMI change from 34.0th to 37.4th percentile). Conclusion. Higher body fat content at baseline was independently associated with a worse response to treatment with TNF-a blockers, measured by ASDAS-CRP and BASDAI change, and might contribute to the lower response rates in female patients. Also, there is a trend toward muscle mass recovery in male patients after treatment.",
keywords = "Ankylosing spondylitis, Body composition, Fat, Mass, Muscle, Sex",
author = "Vodnizza, {Sebasti{\'a}n E.Ib{\'a}{\~n}ez} and Nurmohamed, {Michael T.} and Visman, {Ingrid M.} and {Christiaan Van Denderen}, J. and Lems, {Willem F.} and Francisca Jaime and {Van Der Horst-Bruinsma}, {Irene E.}",
year = "2017",
month = "9",
day = "1",
doi = "10.3899/jrheum.170094",
language = "English",
volume = "44",
pages = "1355--1361",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "9",

}

Fat mass lowers the response to tumor necrosis factor-a blockers in patients with ankylosing spondylitis. / Vodnizza, Sebastián E.Ibáñez; Nurmohamed, Michael T.; Visman, Ingrid M.; Christiaan Van Denderen, J.; Lems, Willem F.; Jaime, Francisca; Van Der Horst-Bruinsma, Irene E.

In: Journal of Rheumatology, Vol. 44, No. 9, 01.09.2017, p. 1355-1361.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Fat mass lowers the response to tumor necrosis factor-a blockers in patients with ankylosing spondylitis

AU - Vodnizza, Sebastián E.Ibáñez

AU - Nurmohamed, Michael T.

AU - Visman, Ingrid M.

AU - Christiaan Van Denderen, J.

AU - Lems, Willem F.

AU - Jaime, Francisca

AU - Van Der Horst-Bruinsma, Irene E.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objective. Our main objective was to assess the relationship between body composition (BC) and response to tumor necrosis factor-a (TNF-a) blocker treatment in patients with ankylosing spondylitis (AS). Our secondary objective was to evaluate the change of BC after treatment, accounting for sex and age. Methods. All included patients fulfilled the modified New York criteria for AS and were naive to TNF-a blocker. They were followed for at least 6 months after the start of etanercept or adalimumab. The Ankylosing Spondylitis Disease Activity Score containing C-reactive protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were reported. BC was assessed by whole body dual-energy X-ray absorptiometry. Body fat percentage (BF%), fat mass index (FMI), and fat free mass index (FFMI) were reported as absolute values and as percentiles. Results. Forty-one patients were included (61% men). The median followup was 14.3 months (interquartile range 8.4-19.4). After multivariate regression analysis, more fat at baseline (BF%, FMI, or FMI percentile) was significantly related with a lower chance of achieving a clinically important improvement of the ASDAS-CRP or BASDAI after treatment. The body composition did not change significantly after treatment, but there was a trend toward muscle recovery in men (FFMI change from 34.0th to 37.4th percentile). Conclusion. Higher body fat content at baseline was independently associated with a worse response to treatment with TNF-a blockers, measured by ASDAS-CRP and BASDAI change, and might contribute to the lower response rates in female patients. Also, there is a trend toward muscle mass recovery in male patients after treatment.

AB - Objective. Our main objective was to assess the relationship between body composition (BC) and response to tumor necrosis factor-a (TNF-a) blocker treatment in patients with ankylosing spondylitis (AS). Our secondary objective was to evaluate the change of BC after treatment, accounting for sex and age. Methods. All included patients fulfilled the modified New York criteria for AS and were naive to TNF-a blocker. They were followed for at least 6 months after the start of etanercept or adalimumab. The Ankylosing Spondylitis Disease Activity Score containing C-reactive protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were reported. BC was assessed by whole body dual-energy X-ray absorptiometry. Body fat percentage (BF%), fat mass index (FMI), and fat free mass index (FFMI) were reported as absolute values and as percentiles. Results. Forty-one patients were included (61% men). The median followup was 14.3 months (interquartile range 8.4-19.4). After multivariate regression analysis, more fat at baseline (BF%, FMI, or FMI percentile) was significantly related with a lower chance of achieving a clinically important improvement of the ASDAS-CRP or BASDAI after treatment. The body composition did not change significantly after treatment, but there was a trend toward muscle recovery in men (FFMI change from 34.0th to 37.4th percentile). Conclusion. Higher body fat content at baseline was independently associated with a worse response to treatment with TNF-a blockers, measured by ASDAS-CRP and BASDAI change, and might contribute to the lower response rates in female patients. Also, there is a trend toward muscle mass recovery in male patients after treatment.

KW - Ankylosing spondylitis

KW - Body composition

KW - Fat

KW - Mass

KW - Muscle

KW - Sex

UR - http://www.scopus.com/inward/record.url?scp=85028856270&partnerID=8YFLogxK

U2 - 10.3899/jrheum.170094

DO - 10.3899/jrheum.170094

M3 - Article

VL - 44

SP - 1355

EP - 1361

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 9

ER -